GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis

GSK has dumped one of its top pipeline prospects. While two of the three phase 3 trials of otilimab hit their primary endpoints, the Big Pharma concluded the efficacy fell short of the level needed to take the anti-GM-CSF antibody forward in rheumatoid arthritis (RA).